Navigation Links
Omni Bio Pharmaceutical Intends to Expand Type 1 Diabetes Trial to 50 Patients
Date:2/28/2011

ase are forward-looking statements that reflect management's current views and expectations with respect to future events, including the expansion and commencement of clinical trials and the outcome and expenses of such trials.  These forward-looking statements are not a guarantee of future events and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual events to differ materially from those expressed or implied by the statements.  These risks and uncertainties are based on a number of factors, including but not limited to receipt of adequate funding to expand and commence clinical trials; receipt of applicable regulatory approvals for clinical trials, the risks related to the ownership and enforceability of our licensed intellectual property necessary to conduct the clinical trials and the business risks disclosed in our SEC filings, especially the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.Omni Bio Pharmaceutical, Inc.

Hayden IR  Edward C. Larkin, Chief Operating Officer

Brett Maas, Managing Partner(720) 488-4708

(646) 536-7331Email: brett@haydenir.com   - or -Cameron Donahue, Partner(651) 653-1854Email: cameron@haydenir.com
'/>"/>

SOURCE Omni Bio Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... CHADDS FORD, Pa. , Jan. 19 ... partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. ... Inc. advising of the filing of an Abbreviated New Drug ... (lidocaine topical patch 5%). , The company is currently reviewing ...
... Partners Forge Collaboration to Fund Discovery of New Drugs that Target the ... MILAN, Italy , Jan. 19 Fast Forward, LLC ... Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF) , ... diabetes in the world today announced a collaborative partnership with Axxam SpA ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 2Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 3Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 4Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 5Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 2Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 3Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 4Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 5
(Date:4/22/2014)... Association for Molecular Pathology (AMP) released a report ... on recommendations for a molecular diagnostics curriculum ... education. The report was prepared by the Medical ... AMP Training and Education Committee. "Our goal was ... medical laboratory scientists appropriately in order to manage ...
(Date:4/22/2014)... the standard measurement for assessing glycemic control over time ... typically measured every few months in a laboratory, but ... estimates A1c using self-monitored blood glucose (SMBG) readings, as ... DTT ), a peer-reviewed journal from Mary Ann Liebert, ... DTT website at http://www.liebertpub.com/dtt . , ...
(Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
(Date:4/22/2014)... news release is available in German . ... Perutz Laboratories of the University of Vienna and the Medical ... have now shown how double stranded RNA, such as viral ... cell. During the immune response against viral infection, the protein ... There it modifies viral RNA to inhibit reproduction of the ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... The Reeve Foundation debuts new national ad campaign giving ... HILLS, N.J., Nov. 3 The Christopher & Dana ... advertising,campaign. The campaign presents an edgier side of the ... life is like through the eyes of,someone living with ...
... critical need to review current treatment strategies for the ... to a series of international papers in the November ... with severe disability, unmet treatment need and little clinical ... Professor David W Dodick from the Mayo Clinic College ...
... 3 Pregis Corporation, a leading,international manufacturer, ... specialty packaging solutions, will conduct an investor,conference ... results on Friday,November 14, 2008 at 10:00 ... 617-614-4909; Participant Passcode: 68623125. A replay of,the ...
... crucial element in hip,fracture recovery, ROSEMONT, Ill., ... fracture are referred to their primary care physicians ... published in the,November 2008 issue of The Journal ... an osteoporosis management program initiated by an,orthopaedic surgeon ...
... LifeNet Health,a leading allograft bio-implant company, ... United States Food and Drug Administration (FDA) ... technology., LifeNet Health received clearance for ... donor cells from cardiovascular tissues,while retaining the ...
... (Nasdaq: BMRN ) announced today the initiation ... with the lysosomal storage disease,Mucopolysaccharidosis Type IVA (MPS ... augment available data on the disease by measuring ... patients.,BioMarin expects to follow the MorCAP program with ...
Cached Medicine News:Health News:Christopher & Dana Reeve Foundation Launches First-Ever National Advertising Campaign 2Health News:Urgent need for research into the best treatment for medication overuse headaches 2Health News:Urgent need for research into the best treatment for medication overuse headaches 3Health News:Urgent need for research into the best treatment for medication overuse headaches 4Health News:Treating Osteoporosis After Hip Fracture 2Health News:Treating Osteoporosis After Hip Fracture 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: